3 Growth Stocks That Could Skyrocket in the Second Half of 2026
Key Points
Arista Networks is benefiting from data center networking demand and strong margins.
Micron is riding the AI memory cycle with explosive revenue growth and upbeat guidance.
Eli Lilly is growing fast thanks to Mounjaro and Zepbound, and raised revenue guidance.
- 10 stocks we like better than Micron Technology ›
The stock market has no shortage of companies promising explosive growth. And sometimes those promises come true. If you doubt that, just compare the list of trillion-dollar companies from five years ago to today. Finding the next wave, though, is a different challenge altogether.
Some growth stocks are fueled mostly by excitement or legitimate secular tailwinds, but they still haven't proved their businesses can catch up with the hype. Others are supported by strong execution, real revenue growth, and the same forces pushing their industries forward.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
That's what makes these three stocks worth a closer look. Arista Networks (NYSE: ANET), Micron Technology (NASDAQ: MU), and Eli Lilly (NYSE: LLY) aren't just good stories, they're recognized leaders with earnings power and plenty of Wall Street attention. Here's why each one could have a strong second half of 2026.
Image source: Getty Images.
Arista Networks: Riding the data center boom
Arista makes networking equipment that helps connect the enormous number of servers, GPUs, and other computing infrastructure packed inside modern data centers. And with data center spending accelerating to record highs, Arista is exactly where it needs to be to take advantage of that momentum.
Its latest quarterly filing proves that claim. The company just delivered its first $3 billion (in revenue) quarter while maintaining a GAAP (generally accepted accounting principles) operating margin of 45%. Lastly, GAAP diluted EPS landed at $.095 per share, up from $0.70 last year.
"As we deliver our first $3 billion quarter in Q2 2026, it is clear that our Arista 2.0 platform strategy is compelling," said CEO Jayshree Ullal. Wall Street seems to agree. According to BarChart, Arista has a consensus strong buy rating with all green marks across the board. Meanwhile, the highest target price suggests up to 57% potential upside.
Micron Technology: Cashing in on the AI memory cycle
Of course, we can't talk about artificial intelligence without mentioning Micron. The memory maker struck gold when it shifted its focus to higher-margin high bandwidth memory (HBM) production to meet hyperscaler demands. It's now one of the top three memory-chip manufacturers in the world, right up there with Samsung and SK Hynix.
That market leadership is reflected in its income statement. In the quarter reported in late June, the company notched $41.5 billion in revenue, representing massive 346% year-over-year growth. The vast majority of this revenue came from its DRAM technology umbrella, under which HBM falls. Meanwhile, diluted earnings per share reached $25.11 compared to last year's $1.91.
Current-quarter guidance makes the picture even rosier. Revenue is slated to hit $51 billion while diluted earnings are expected to reach $32, both on the high end. It may also be why analysts rate Micron a strong buy, with the highest target price suggesting the stock could more than double over the next year.
Eli Lilly: Betting big beyond AI
Rounding out this list is Eli Lilly, which has absolutely nothing to do with the AI supercycle. Instead, it's digging through a different gold rush: diabetes and obesity treatments.
In its recent quarterly report, the company reported revenue growth of 48% to $23 billion. That growth was driven by Mounjaro and Zepbound, Eli Lilly's blockbuster GLP-1 drugs. Mounjaro revenue jumped 91% year over year to nearly $9.9 billion, while Zepbound generated about $4.9 billion, up 46%.
The sheer scale of demand has prompted Lilly to raise its full-year 2026 revenue guidance to $85 billion to $87 billion. At the same time, high target prices indicate a 28% potential upside. That just goes to show that its tirzepatide-based drugs are riding a wave that shows no sign of cresting.
The common thread
All three companies have the scale and brand recognition that come with their market leadership. But the most common thread between them is that secular tailwinds are driving their numbers -- and their stock prices -- higher.
That doesn't make them risk-free. No stock is, even in a market that feels this optimistic. But if you're looking for growth stocks that could outperform in the second half of 2026, Arista, Micron, and Eli Lilly bring a mix of momentum, real earnings power, and narratives that investors continue to reward.
That's the setup for the kind of move that can feel like a "skyrocket" by year-end, even if the path there is not perfectly smooth.
Should you buy stock in Micron Technology right now?
Before you buy stock in Micron Technology, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Micron Technology wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $429,223!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,317,883!*
Now, it’s worth noting Stock Advisor’s total average return is 965% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of August 23, 2026.
Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Arista Networks, Eli Lilly, and Micron Technology. The Motley Fool has a disclosure policy.
